5 articles suggested by Vivek Subbiah

Vivek Subbiah shared a few must-reads paper on X:

1. Dose selection of novel anticancer drugs: exposing the gap between selected and required doses

Authors: Catharina J P Op ‘t Hoog, Niven Mehra, Marc Maliepaard, Kalijn Bol, Prof Hans Gelderblom, Prof Gabe S Sonke, Adrianus J de Langen, Niels W C J van de Donk, Jeroen J W M Janssen, Prof Monique C Minnema, Prof Nielka P van Erp, Emmy Boerrigter, 

2. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Authors: Georgina V. Long, Evan J. Lipson, F. StephenHodi, Paolo A. Ascierto, James Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A. Sakkal, Hussein Tawbi, and Dirk Schadendorf

5. Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase InhibitorsA Nonrandomized Controlled Trial

Authors: Min Hee Hong, Yoon Ji Choi, Hee Kyung Ahn, Sun Min Lim, Bhumsuk Keam, Dong-Wan Kim, Tae Min Kim, Jeonghwan Youk, Yu Jung Kim, Shinwon Hwang, Sangwoo Kim, Ju Won Kim, Hye Ryun Kim, Jin Hyoung Kang,

A
Source: Vivek Subbiah/X

Read more posts by Vivek Subbiah on oncodaily.com

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.